High density lipoprotein in patients with liver failure; Relation to sepsis, adrenal function and outcome of illness

Liver International

Volumn 32, Issue 1, 2012, Pages 128-136

  Atogo Asse, Frederique Estelle ^a   Vincent, Royce P ^a   Hughes, Sarah A ^a   Auzinger, Georg ^a   Le Roux, Carel W ^a   Wendon, Julia ^a   Bernal, William ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cortisol; Critical illness; HDL; Liver failure

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE;

ACCURACY; ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ADRENAL FUNCTION; ADULT; ARTICLE; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LIPID ANALYSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SEPSIS;

ADRENAL GLANDS; ADRENAL INSUFFICIENCY; ADULT; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; END STAGE LIVER DISEASE; FEMALE; GREAT BRITAIN; HUMANS; LIPOPROTEINS, HDL; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE;

EID: 83255193994     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02657.x     Document Type: Article

References (40)

1. Tsai M-H, Peng Y-S, Chen Y-C, Lien J-M, Tian Y-C, Fang J-T, et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. J Hepatol 2009; 50: 906-15.
2. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792-6.
3. Powell EE, Kroon PA. Liver, lipoproteins and disease: II. Clinical relevance of disordered cholesterol metabolism in liver disease. J Gastroenterol Hepatol 1992; 7: 225-31.
4. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007; 33: 13-24.
5. Kraemer FB. Adrenal cholesterol utilization. Mol Cell Endocrinol 2007; 266: 42-5.
6. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36: 1937-49.
7. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006; 43: 673-81.
8. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36: 395-402.
9. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
10. Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008; 118: 364-75.
11. Berbee JFP, Havekes LM, Rensen PCN. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005; 11: 97-103.
12. Birjmohun RS, van Leuven SI, Levels JHM, van 't Veer C, Kuivenhoven JA, Meijers JCM, et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007; 27: 1153-8.
13. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-64.
14. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007; 33: 25-35.
15. Van der Voort PHJ, Gerritsen RT, Bakker AJ, Boerma EC, Kuiper MA, de Heide L. HDL-cholesterol level and cortisol response to synacthen in critically ill patients. Intensive Care Med 2003; 29: 2199-203.
16. Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert F-X, Gluck T, et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 2009; 35: 1877-85.
17. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A, et al. Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol 2008; 97: 227-33.
18. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-5.
19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
20. Kamath PS, Kim WR. Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.
21. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
22. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
23. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.
24. Habib A, Mihas AA, Abou-Assi SG, Williams LM, Gavis E, Pandak WM, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol 2005; 3: 286-91.
25. Miyazaki M, Kato M, Tanaka M, Takayanagi R. High-density lipoprotein cholesterol improves the model for end-stage liver disease scoring system for prognostic prediction of acute liver failure. Scand J Gastroenterol 2010; 45: 506-8.
26. Jiang M, Liu F, Xiong W-J, Zhong L, Xu W, Xu F, et al. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol 2010; 16: 1397-401.
27. Galbois A, Thabut D, Tazi KA, Rudler M, Mohammadi MS, Bonnefont-Rousselot D, et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology 2009; 49: 175-84.
28. McDonald JA, Handelsman DJ, Dilworth P, Conway AJ, McCaughan GW. Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. J Gastroenterol Hepatol 1993; 8: 247-53.
29. Zumoff B, Bradlow HL, Gallagher TF, Hellman L. Cortisol metabolism in cirrhosis. J Clin Invest 1967; 46: 1735-43.
30. Marik PE, Gayowski T, Starzl TE, Hepatic Cortisol R. Adrenal Pathophysiology Study G. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005; 33: 1254-9.
31. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology 2006; 44: 1288-95.
32. Marik PE. Critical illness-related corticosteroid insufficiency. Chest 2009; 135: 181-93.
33. Bornstein SR. Predisposing factors for adrenal insufficiency. N Eng J Med 2009; 360: 2328-39.
34. Borkowski AJ, Levin S, Delcroix C, Mahler A, Verhas V. Blood cholesterol and hydrocortisone production in man: quantitative aspects of the utilization of circulating cholesterol by the adrenals at rest and under adrenocorticotropin stimulation. J Clin Invest 1967; 46: 797-811.
35. Van Leeuwen HJ, Heezius ECJM, Dallinga GM, van Strijp JAG, Verhoef J, van Kessel KPM. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003; 31: 1359-66.
36. Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med 2006; 32: 275-80.
37. Tan T, Chang L, Woodward A, McWhinney B, Galligan J, Macdonald GA, et al. Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol 2010; 53: 841-8.
38. Annane D, Bellissant E, Bollaert P-E, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. Jama 2009; 301: 2362-75.
39. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Eng J Med 2008; 358: 111-24.
40. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int 2003; 23: 71-7.